The Effects of Pyrrolo[1,2-b][1,2,5]Benzothiadiazepines in MEC1 Cells

Journal of Cellular Biochemistry

Volumn 116, Issue 2, 2015, Pages 339-349

  Maffei, Gabriella ^a   Mirone, Giovanna ^b   Perna, Stefania ^a   Di Stefano, Carla ^c  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Akt; Autophagy; B cell leukemia cells; BAX BCL 2 ratio; PBTDs

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOPHAGY PROTEIN 5; BECLIN 1; BENZODIAZEPINE DERIVATIVE; CASPASE 3; CASPASE 9; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PYRROLO[1,2 B][1,2,5]BENZOTHIADIAZEPINE; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; ATG5 PROTEIN, HUMAN; BECN1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; PYRROLE DERIVATIVE; RS2778; THIAZEPINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; CELLS; CONTROLLED STUDY; HUMAN; HUMAN CELL; MEC1 CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; AUTOPHAGY; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFECTS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BCL-2-ASSOCIATED X PROTEIN; BENZODIAZEPINES; BLOTTING, WESTERN; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR STRUCTURE; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; SIGNAL TRANSDUCTION; THIAZEPINES;

EID: 84916613377     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24977     Document Type: Article

References (43)

1. Abbott BL. 2006. Chronic lymphocytic leukemia: Recent advances in diagnosis and treatment. Oncologist 11:21-30.
2. Adams JM. 2003. Ways of dying: Multiple pathways to apoptosis. Genes Dev 17:2481-2495.
3. Arico S, Petiot A, Bauvy C, Dubbelhuis PF, Meijer AJ, Codogno P, Ogier-Denis E. 2001. The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 276:35243-35246.
4. Barragán M, Campas C, Bellosillo B, Gil J. 2003. Protein kinases in the regulation of apoptosis in B-cell chronic lymphocytic leukemia cells. Leuk Lymphoma 44:1865-1870.
5. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JW, Rai K, Schiffer CA, Larson RA. 2003. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6-14.
6. Capitani N, Baldari CT. 2010. The Bcl-2 family as a rational target for the treatment of B-cell chronic lymphocytic leukaemia. Curr Med Chem 17:801-811.
7. Chiorazzi N, Ferrarini M. 2003. B cell chronic lymphocytic leukemia: Lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 21:841-894.
8. Cui Q, Tashiro S, Onodera S, Ikejima T. 2006. Augmentation of oridonin-induced apoptosis observed with reduced autophagy. J Pharmacol Sci 101:230-239.
9. Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sánchez A, Martín-Saavedra FM, Ballester S, García-Marco J, Jordá J, Durántez A. 2004. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 18:1391-1400.
10. Dighiero G, Hamblin DJ. 2008. Chronic lymphocytic leukemia. Lancet 371:1017-1029.
11. Di Stefano C, Marfe G, Trawinska MM, Sinibaldi Salimei P, Silvestri R, Amadori S, Abruzzese E. 2010. Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) exert their anti-proliferative activity by interfering with Akt-mTOR signaling and bax:bcl-2 ratio modulation in cells from chronic myeloid leukemic patients. Cancer Science 101:991-1000.
12. Dores GM, Anderson WF, Curtis RE, Landgren O, Ostroumova E, Bluhm EC, Rabkin CS, Devesa SS, Linet MS. 2007. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 139:809-819.
13. Dourmashkin LR, Allen PD, Gray AB, Newland AC, Kelsey SM. 1997. Inhibition of autophagy abrogates tumour necrosis factor α induced apoptosis in human T-lymphoblastic leukaemic cells. Br Haematol 98:673-685.
14. Escobar-Díaz E, López-Martín EM, Hernández del Cerro, Puig-Kroger M, Soto-Cerrato A, Montaner V, Giralt B, García-Marco E, Pérez-Tomás JA, Garcia-Pardo RA. 2005. AT514, a cyclic depsipeptide from Serratia marcescens, induces apoptosis of B-chronic lymphocytic leukemia cells. Interference with the Akt/NF-κB survival pathway. Leukemia 19:572-579.
15. Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao W, Eshraghi M, Bus CJ, Kadkhoda K, Wiechec E, Halayko AJ, Los M. 2009. Apoptosis and cancer: Mutations within caspase genes. J Med Genet 46:497-510.
16. Glick D, Barth S, Macleod KF. 2010. Autophagy: Cellular and molecular mechanisms. J Pathol 221:3-12.
17. González-Polo RA, Boya P, Pauleau AL, Jalil A, Larochette N, Souquère S, Eskelinen EL, Pierron G, Saftig P, Kroemer G. 2005. The apoptosis/autophagy paradox: Autophagic vacuolization before apoptotic death. J Cell Sci 118:3091-3102.
18. Hallaert DY, Spijker R, Jak M, Derks IA, Alves NL, Wensveen FM, de Boer JP, de Jong D, Green SR, van Oers MH, Eldering E. 2007. Crosstalk among Bcl-2 family members in B-CLL: Seliciclib acts via the Mcl 1/Noxa axis and gradual exhaustion ofBcl-2 protection. Cell Death Differ 14:1958-1967.
19. Hallek M, Fingerle-Rowson Fink, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, Uvon Gruenhagen, Bergmann U, Catalano MA, Zinzani J, Caligaris PL, Cappio F, Seymour JF, Berrebi A, Jaeger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Boettcher S, Ritgen M, Mendila M, Kneba M, Hartmut Doehner, Stilgenbauer S, Fischer K. 2009. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group. Blood 114:Abstract535.
20. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ. 2010. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116:2078-2088.
21. Herrmann M, Lorenz HM, Voll R, Grunke M, Woith W, Kalden JR. 1994. A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res 22:5506-5507.
22. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, Sirard C, Mayer J. 2007. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616-5623.
23. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. 2005. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088.
24. Klionsky DJ, Emr SD. 2000. Autophagy as a regulated pathway of cellular degradation. Science 290:1717-1721.
25. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Tremmel L, Merkle K, Montillo M. 2009. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:4378-4384.
26. Kolb JP, Kern C, Quiney C, Roman V, Billard C. 2003. Reestablishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr Drug Targets Cardiovasc Haematol Disord 3:261-286.
27. Levine B, Sinha S, Kroemer G. 2008. Bcl-2 family members: Dual regulators of apoptosis and autophagy. Autophagy 4:600-606.
28. Li H, Wang P, Sun Q, Ding WX, Yin XM, Sobol RW, Stolz DB, Zhang L. 2011. Following Cytochrome c Release, Autophagy Is Inhibited during Chemotherapy-Induced Apoptosis by Caspase 8-Mediated Cleavage of Beclin 1. Cancer Res 71:3625-3634.
29. Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P, Sica S, Leone G, Efremov DG. 2007. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 21:110-120.
30. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E, Los M. 2007. Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy. Drug Resist Updat 10:13-29.
31. Marfe G, Di Stefano C, Silvestri R, Abruzzese E, Catalano G, Di Renzo L, Filomeni G, Giorda E, La Regina G, Morgante E, Ciriolo MR, Russo MA, Amadori S, Sinibaldi-Salimei P. 2007. PYRROLO[1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs) induce apoptosis in K562 cells. BMC Cancer 7:207.
32. Marfe G, Di Stefano C. 2010. In vitro anti-leukaemia activity of pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs). Recent Pat Anticancer Drug Discov 5:58-68.
33. Noda T, Fujita N, Yoshimori T. 2009. The late stages of autophagy: How does the end begin? Cell Death Differ 16:984-999.
34. Peng XZ, Chen Y, Piao YJ. 2004. Inhibition of autophagy influences the autophagic apoptosis induced by vincristine. Tumor 24:32-34.
35. Petiot A, Ogier-Denis E, Blommaart EF, Meijer AJ, Codogno P. 2000. Distinct classes of phosphatidylinositol 3′-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J Biol Chem 275:992-998.
36. Pleyer L, Egle A, Hartmann TN, Greil R. 2009. Molecular and cellular mechanisms of CLL: Novel therapeutic approaches. Nat Rev Clin Oncol 6:405-418.
37. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. 1975. Clinical staging of chronic lymphocytic leukemia. Blood 46:219-234.
38. Shanafelt TD. 2009. Predicting clinical outcome in CLL: How and why. Hematology Am Soc Hematol Educ Program 1:421-429.
39. Silvestri R, Marfè G, Artico M, La Regina G, Lavecchia A, Novellino E, Morgante E, Di Stefano C, Catalano G, Filomeni G, Abruzzese E, Ciriolo MR, Russo MA, Amadori S, Cirilli R, La Torre F, Sinibaldi Salimei. 2006. Pyrrolo [1,2-b][1,2,5]benzothiadiazepines (PBTDs): A new class of agents with high apoptotic activity in chronic myelogenous leukemia K562 cells and in cells from patients at onset and who were imatinib-resistant. J Med Chem 49:5840-5844.
40. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR, Martin SJ. 1999. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 144:281-292.
41. Tam CS, Keating MJ. 2010. Chemoimmunotherapy of chronic lymphocytic leukemia. Nat Rev Clin Oncol 7:521-532.
42. Wierda WG, Chiorazzi N, Dearden C, Brown JR, Montserrat E, Shpall E, Stilgenbauer S, Muneer S, Grever M. 2010. Chronic lymphocytic leukemia: New concepts for future therapy. Clin Lymphoma Myeloma Leuk 10:369-378.
43. Witzig TE, Kaufmann SH. 2006. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 7:285-294.